ESTERN Medical CRO Life Sciences, led by its President & Chief Medical Officer Dr. Jorge Estrella, participated as a KOL at The Economist Antibodies Inc: America’s Healthcare Revolution Virtual Roundtable

This past week Dr. Jorge Estrella, President & Chief Medical Officer at ESTERN Medical CRO Life Sciences, was part virtual round table as of the Key Opinion Leaders (KOLs) at The Economist Antibodies Inc: America’s Healthcare Revolution Virtual Roundtable meeting, sharing his expertise in “The Clinical Development Research in COVID-19 in the pharmaceutical, medical device and diagnostic imaging fields.”

Dr. Estrella did mention that this exclusive, high-level roundtable dialogue discussed how to address challenges in US North America’s healthcare system, how the public and private sector can collaborate to improve access and reduce financial costs, and how stakeholders can collaborate to improve outcomes for all life science sectors.

Dr. Estrella has comment as US North America boasts some of the most innovative healthcare life sciences companies in the world across a number of research and development sectors such as pharmaceuticals, biotechnology, medical device makers and insurance firms and vanguard innovation universities and labs lead the world in cutting-edge medical research, whit top-tier specialist hospitals provide top-grade treatments and care for major diseases and rare disease conditions alike, however we are still not able to develop the correct health plan for quality of life to our patients. 

But overall, healthcare in US North America is very expensive. The US spends nearly one-fifth of its GDP, or around $3.5 trillion US/Dlls on healthcare per year. Higher spending typically results in better outcomes, but the US patients fare no better than those in other developed or emerging countries.

Dr. Estrella explains that Healthcare has become even more critical to the economy and the country’s long-term prospects since this current Covid-19 pandemic outbreak crisis. Among the list of priorities are cutting financial costs, harnessing the newest R&D science and breakthroughs for newer treatment products, for improving the US population access to patient care, bringing together the various intermediaries, and clearly defining the priorities and opportunities to create newer jobs and investment in this crucial pandemic sector to the global economies.   

Dr. Estrella looking ahead in 2021, how will America’s health sector evolve, and what will it mean for stakeholders from Pharmaceutical, Biotech’s, Medical Device & CROs and most important our patients, physicians’ practitioners, health insurers.